Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Delbaldo

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The Cochrane Database of Systematic Reviews|October 19, 2007
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseCatherine Delbaldo, Stefan Michiels, Estelle Rolland, et al.
The Cochrane Database of Systematic Reviews|April 20, 2012
WITHDRAWN: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseCatherine Delbaldo, Stefan Michiels, Estelle Rolland, et al.
Journal of the American Academy of Dermatology|May 11, 2002
Drug-induced epidermolysis bullosa acquisita with antibodies to type VII collagenCatherine Delbaldo, Mei Chen, André Friedli, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2008
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignanciesSandrine Faivre, Catherine Delbaldo, Valérie Boige, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Population pharmacokinetics and pharmacogenetics of imatinib in children and adultsAurélie Petain, Darouna Kattygnarath, Julie Azard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumorsCatherine Delbaldo, Etienne Chatelut, Micheline Ré, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2005
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinomaCatherine Delbaldo, Jean-Yves Pierga, Véronique Dieras, et al.
Oncology|July 23, 2011
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinomaElias Assaf, Muriel Verlinde-Carvalho, Catherine Delbaldo, et al.
Bulletin Du Cancer|September 25, 2018
[Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study)]Mireille Favier, Fabienne Le Goc-Sager, Isabelle Vincent-Cantini, et al.
Archives of Surgery (Chicago, Ill. : 1960)|July 20, 2007
Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administrationMehdi Karoui, Antoine Charachon, Catherine Delbaldo, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The Cochrane Database of Systematic Reviews|October 19, 2007
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseCatherine Delbaldo, Stefan Michiels, Estelle Rolland, et al.
The Cochrane Database of Systematic Reviews|April 20, 2012
WITHDRAWN: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseCatherine Delbaldo, Stefan Michiels, Estelle Rolland, et al.
Journal of the American Academy of Dermatology|May 11, 2002
Drug-induced epidermolysis bullosa acquisita with antibodies to type VII collagenCatherine Delbaldo, Mei Chen, André Friedli, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2008
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignanciesSandrine Faivre, Catherine Delbaldo, Valérie Boige, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Population pharmacokinetics and pharmacogenetics of imatinib in children and adultsAurélie Petain, Darouna Kattygnarath, Julie Azard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumorsCatherine Delbaldo, Etienne Chatelut, Micheline Ré, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2005
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinomaCatherine Delbaldo, Jean-Yves Pierga, Véronique Dieras, et al.
Oncology|July 23, 2011
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinomaElias Assaf, Muriel Verlinde-Carvalho, Catherine Delbaldo, et al.
Bulletin Du Cancer|September 25, 2018
[Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study)]Mireille Favier, Fabienne Le Goc-Sager, Isabelle Vincent-Cantini, et al.
Archives of Surgery (Chicago, Ill. : 1960)|July 20, 2007
Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administrationMehdi Karoui, Antoine Charachon, Catherine Delbaldo, et al.
Pageof 3